Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Optimizing Cough Rehabilitation Through Combined Cough Skill Training and Transcutaneous Spinal Cord Stimulation (Optimizing Cou)

17. november 2026 oppdatert av: University of Florida

The goal of this clinical trial is to evaluate the effects of combining cough training with low-level electrical stimulation to the neck (tsDCS) in healthy adults and adults with neurological diseases. The main questions it aims to answer are:

  • Is using tsDCS during cough training safe, tolerable, and acceptable to participants?
  • What tsDCS settings are most effective for pairing with cough training? Researchers will compare sham stimulation with active tsDCS to see if tsDCS enhances cough gains. Before and after each testing session, participants will complete breathing, coughing, and respiratory-strength training.

Studieoversikt

Status

Har ikke rekruttert ennå

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

Study Purpose and Background People with neurodegenerative diseases frequently experience reduced cough function (hypotussia) and swallowing difficulties (dysphagia), which negatively impact quality of life and increase the risk of pneumonia, a leading cause of death in these populations. While behavioral exercises like cough training can help improve airway protection, people with these diseases often struggle to perform them with the high intensity required to trigger lasting brain and nerve adaptation (neuroplasticity).

To overcome this limitation, this pilot study investigates a novel, non-invasive combinatorial approach: pairing Cough Skill Training (CST) with transcutaneous spinal direct current stimulation (tsDCS) applied to the neck. The theory is that spinal stimulation enhances communication between the brain and muscles, optimizing the outcomes of training. Because this combined intervention has not been tested before, this initial research aims to establish its overall feasibility and compare different stimulation settings in healthy adults before future translation to clinical patient populations.

Study Design and Methods This study is an initial pilot trial utilizing a randomized crossover design involving 16 healthy adult participants aged 40 to 85 years with normal respiratory function.

  • Screening & Familiarization (Visit 1): Participants undergo baseline screening, including health history reviews and spirometry (pulmonary function testing). They are also familiarized with the testing and training activities.
  • Intervention Sessions: Across separate intervention visits separated by a 6-week washout period, participants receive 20 minutes of neck-based tsDCS paired with CST. During active stimulation, current is delivered continuously, whereas sham stimulation provides brief ramping periods without sustained current. CST involves visual feedback on a computer screen to guide participants through coughing at specific target ranges (strong, moderate, and weak).
  • Assessments: Researchers record vital signs, breathing tests, airway occlusions (to measure drive to breathe), maximum respiratory pressure tests. Exploratory measures, such as saliva swallowing patterns and how long participants can produce a vowel sound, are also tracked.

Aims:

  • Aim 1: Feasibility and acceptability will be evaluated by the participants' ability to complete all training tasks simultaneously with stimulation, scores from the Acceptability of Intervention Measure (AIM), participant ability to blind/detect sham versus active treatment, and perceived exertion, task difficulty, and stimulation intensity ratings.
  • Aim 2: Cough and respiratory performance will be measured by the change in cough peak expiratory flow rate (PEFR) from baseline, along with CST performance accuracy, other cough, resting breathing, and respiratory strength parameters.

Studietype

Intervensjonell

Registrering (Antatt)

16

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

  • Navn: May Smith-Hublou, PhD, SLP
  • Telefonnummer: 352-273-6855
  • E-post: maysmith@ufl.edu

Studer Kontakt Backup

  • Navn: Barbara K Smith, PhD, PT
  • Telefonnummer: 352-294-5315

Studiesteder

    • Florida
      • Gainesville, Florida, Forente stater, 32610
        • University of Florida
        • Ta kontakt med:
        • Hovedetterforsker:
          • May Smith-Hublou, PhD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

40 år til 85 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Forced vital capacity (FVC) ≥ 80% predicted based on age/sex

Exclusion Criteria:

  • neurological disease
  • respiratory disease including acute respiratory infection with cough during past week
  • Pregnancy
  • metallic implants in the spine
  • cardiac pacemaker
  • use of sodium channel blockers, calcium channel blockers, and/or NMDA receptor antagonists

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Crossover-oppdrag
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Sham-komparator: Sham Stimulation

Transcutaneous spinal cord stimulation at reduced intensity, lasting 1 minute at the beginning and end of a 20-minute session.

CST involves visual feedback on a computer screen to guide participants through coughing at specific target ranges (strong, moderate, and weak).

Transcutaneous spinal cord stimulation at reduced intensity, lasting 1 minute at the beginning and end of a 20-minute session.

Eksperimentell: Cathodal Stimulation

Transcutaneous spinal cord stimulation at 2mA intensity, for 20 minutes.

CST involves visual feedback on a computer screen to guide participants through coughing at specific target ranges (strong, moderate, and weak).

Transcutaneous spinal cord stimulation at 2mA intensity, for 20 minutes.

Eksperimentell: Anodal Stimulation

Transcutaneous spinal cord stimulation at 2mA intensity, for 20 minutes.

CST involves visual feedback on a computer screen to guide participants through coughing at specific target ranges (strong, moderate, and weak).

Transcutaneous spinal cord stimulation at 2mA intensity, for 20 minutes.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Completion of training tasks with simultaneous stimulation
Tidsramme: During training

Measured as percentage of sessions in which both interventions can be completed simultaneously.

During training
Peak Cough Flow
Tidsramme: Baseline, immediate post-single-treatment measurement

The highest rate of airflow generated during a volitional cough

Baseline, immediate post-single-treatment measurement

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Acceptability of Intervention Measure (AIM)
Tidsramme: Immediate post-single-treatment measurement

Participants will rate favorability of treatment procedures. This scale consists of 4 items rating acceptability using a 1-5 Likert Scale, with a combined total score range of 4-20. A score of 1 represents "completely disagree," and a score of 5 represents "completely agree." Thus, a higher score reflects a more favorable experience.

Immediate post-single-treatment measurement

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Airway occlusion pressure (P0.1)
Tidsramme: Baseline vs immediate post-single-treatment

The change in air pressure at the opening of the airway (mouth and nose) in the first 100 ms of a breath. This estimates neural drive to breathe.

Baseline vs immediate post-single-treatment

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Samarbeidspartnere

Etterforskere

  • Hovedetterforsker: May Smith-Hublou, PhD, University of Florida

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. desember 2026

Primær fullføring (Antatt)

30. september 2027

Studiet fullført (Antatt)

31. desember 2027

Datoer for studieregistrering

Først innsendt

15. oktober 2026

Først innsendt som oppfylte QC-kriteriene

17. november 2026

Først lagt ut (Faktiske)

18. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

17. november 2026

Sist bekreftet

1. mai 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • IRB202600626

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Participant data that underlie the results reported in this article after deidentification.

IPD-delingstidsramme

9 months and ending 36 months following article publication.

Tilgangskriterier for IPD-deling

Investigators whose proposed use of the data has been approved by an independent review committee.

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Ja

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .